<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Opportunities center on personalized medicine, biologics, AI-led design, novel excipients and advanced delivery, with Asia-Pacific, local sourcing and fixed-dose combinations gaining traction.Dublin, Sept. 14, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.researchandmarkets.com/reports/5820041/drug-formulation-market-report?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r6nx52&amp;utm_campaign=2347765+-+Drug+Formulation+Market+Outlook+2026-2030%3a+Investment+Trends%2c+Strategic+Profiles+and+Revenue+Share+Outlook+-+Market+to+Reach+%243.19+Trillion+by+2030+as+Personalized+Medicine+and+Advanced+Drug+Delivery+Accelerate+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Drug Formulation Market Report 2026">"Drug Formulation Market Report 2026"</a> has been added to ResearchAndMarkets.com's offering. The global drug formulation market is experiencing strong growth, rising from $2.04 trillion in 2025 to an estimated $2.22 trillion in 2026 at a compound annual growth rate (CAGR) of 8.6%. Historical market expansion has been supported by increasing demand for generic drugs, the rising prevalence of chronic diseases, advances in pharmaceutical research, broader hospital and clinic networks, and greater investment in research and development. Looking ahead, the drug formulation market is projected to reach $3.19 trillion by 2030, representing a CAGR of 9.5%. Growth during the forecast period is expected to be driven by the emergence of gene and cell therapies, adoption of artificial intelligence in drug design, development of novel excipients, increasing demand for biologics and specialty medicines, and continued expansion of pharmaceutical markets in emerging economies. Key drug formulation market trends include personalized formulations, advanced drug delivery systems, biologics and biosimilars development, and greater emphasis on formulation stability and shelf-life optimization. Pharmaceutical manufacturers are also prioritizing regulatory compliance, quality assurance, treatment effectiveness, and patient safety as therapies become more complex and targeted. The growing adoption of personalized medicine is a major factor supporting market expansion. Treatments informed by patient genetics, biomarkers, and other individual characteristics are increasing demand for customized drug formulations and targeted therapies. This approach is particularly relevant to improving drug response and addressing rare or complex conditions. According to the Personalized Medicine Coalition, personalized medicines accounted for approximately 38% of newly approved therapeutic molecular entities in 2023, up from 34% in 2022. Product innovation is also shaping the competitive landscape. Pharmaceutical businesses are developing fixed-dose combination therapies designed to simplify dosing and improve disease management. In October 2023, Glenmark Pharmaceuticals introduced Zita DM, a once-daily triple-drug combination for patients with type 2 diabetes. The treatment combines Teneligliptin, Dapagliflozin, and Metformin SR to support improved glycemic control. Strategic acquisitions are strengthening drug delivery and pharmaceutical excipient capabilities across the industry. In May 2025, France-based Roquette acquired IFF Pharma Solutions for an undisclosed amount. The transaction is intended to reinforce Roquette's position in the global pharmaceutical excipients market while expanding its innovation portfolio, technical expertise, and capabilities in specialized solutions for oral dosage forms. The drug formulation market spans oral, parenteral, topical, and inhalation dosage forms. Products include tablets, capsules, injectables, sprays, suspensions, powders, and other formats used across cardiovascular disease, diabetes, cancer, respiratory disorders, pain management, and additional therapeutic areas. Demand comes from large pharmaceutical manufacturers, small and medium-sized enterprises, and biotechnology companies seeking formulation optimization, process optimization, and scale-up services. North America was the largest region in the drug formulation market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain. Markets Covered: 1) By Dosage Form: Oral formulations; Parenteral Formulations; Topical Formulations; Inhalation Formulations 2) By Formulation: Tablets; Capsules; Injectable; Sprays; Suspensions; Powders; Other Formulations 3) By Therapy Area: Cardiovascular Diseases (CVDs); Pain; Diabetes; Cancer; Respiratory Diseases; Other Diseases 4) By End-User: Big Pharma; Small And Medium Pharma; Biotech Companies Subsegments: 1) By Oral Formulations: Tablets; Capsules; Powders; Liquids Or Solutions 2) By Parenteral Formulations: Injectables; Implants; Infusions 3) By Topical Formulations: Creams; Ointments; Gels; Transdermal Patches 4) By Inhalation Formulations: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers Time Series: Five years historic and ten years forecast. Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita. Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments. Key Attributes: <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Report Attribute</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">Details</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">No. of Pages</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">250</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecast Period</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">2026 - 2030</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Estimated Market Value (USD) in 2026</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$2.22 Trillion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Forecasted Market Value (USD) by 2030</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">$3.19 Trillion</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-left: solid black 1pt ; ">Compound Annual Growth Rate</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; ">9.5%</td></tr><tr><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; ">Regions Covered</td><td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; ">Global</td></tr></table> Companies Featured The companies featured in this Drug Formulation market report include: <ul><li>AstraZeneca PLC</li><li>The Bristol-Myers Squibb Company</li><li>Eli Lilly and Company</li><li>Gilead Sciences Inc.</li><li>Merck &amp; Co. Inc.</li><li>Novartis AG</li><li>Pfizer Inc.</li><li>AbbVie Inc.</li><li>C.H. Boehringer Sohn AG &amp; Co. KG</li><li>F. Hoffmann-La Roche AG</li><li>Johnson &amp; Johnson</li><li>Bayer AG</li><li>Teva Pharmaceutical Industries Ltd.</li><li>Sanofi S.A.</li><li>GlaxoSmithKline plc</li><li>Novo Nordisk A/S</li><li>Amgen Inc.</li><li>Viatris Inc.</li><li>Sandoz International GmbH</li><li>Takeda Pharmaceutical Company Limited</li><li>Sun Pharmaceutical Industries Ltd.</li><li>Dr. Reddy's Laboratories Ltd.</li><li>Cipla Ltd.</li><li>Lupin Limited</li><li>Torrent Pharmaceuticals Limited</li><li>Jubilant Life Sciences Limited</li><li>Cadila Healthcare Limited</li><li>Glenmark Pharmaceuticals Ltd.</li><li>Wockhardt Ltd.</li><li>Hikma Pharmaceuticals plc</li></ul> For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5820041/drug-formulation-market-report?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=r6nx52&amp;utm_campaign=2347765+-+Drug+Formulation+Market+Outlook+2026-2030%3a+Investment+Trends%2c+Strategic+Profiles+and+Revenue+Share+Outlook+-+Market+to+Reach+%243.19+Trillion+by+2030+as+Personalized+Medicine+and+Advanced+Drug+Delivery+Accelerate+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/7pi0af</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/OGE1NzQ2NDItOTVkMC00Y2EzLWE2YzctMzFlNjIyMTUwMGE3LTEwMjY3MzctMjAyNi0wOS0xNC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

Drug Formulation Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - Market to Reach $3.19 Trillion by 2030 as Personalized Medicine and Advanced Drug Delivery Accelerate Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn